Pasar al contenido principal

DESCIFRANDO LAS BASES MOLECULARES DE LAS ENFERMEDADES RELACIONADAS CON DESREGULACION DEL COMPLEMENTO Y APRENDIENDO COMO TRATARLAS.

SAF2015-66287-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2015
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Dirección General de Investigación Científica y Técnica
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

How novel structures inform understanding of complement function

  • Goicoechea de Jorge, Elena
  • Yébenes, Hugo
  • Serna, Marina
  • Tortajada, Agustín
  • Llorca, Óscar
  • Rodríguez de Córdoba, Santiago
33 p.-3 fig., During the last decade, the complement field has experienced outstanding advancements in the mechanistic understanding of how complement activators are recognized, what C3 activation means, how protein complexes like the C3 convertases and the membrane attack complex are assembled, and how positive and negative complement regulators perform their function. All of this has been made possible mostly because of the contributions of structural biology to the study of the complement components. The wealth of novel structural data has frequently provided support to previously held knowledge, but often has added alternative and unexpected insights into complement function. Here we will review some of these findings focusing in the alternative and terminal complement pathways., SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608) and the Autonomous Region of Madrid (S2010/BMD- 2316). SRdeC is member of the “CIB intramural Program “Molecular Machines for Better Life (MACBET)”. EGdeJ is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (RYC-2013-13395 and SAF2014-52339P). OL is supported by the Spanish Ministry of Economy, Industry and Competitiveness (SAF2014-52301-R).AT and MS are supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (IJCI-2015-25222 and IJCI-2015-24388, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome

  • Goicoechea de Jorge, Elena
  • Tortajada, Agustín
  • Pinto, Sheila
  • Gastoldi, Sara
  • Martín Merinero, Héctor
  • García-Fernández, Jesús
  • Arjona, Emilia
  • Cao, Mercedes
  • Remuzzi, Giuseppe
  • Noris, Marina
  • Rodríguez de Córdoba, Santiago
10 p.-6 fig.-1 tab., Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombotic microangiopathy caused by complement pathogenic variants, mainly affects the kidney microvasculature. A retrospective genetic analysis in our aHUS cohort (n=513) using multiple ligation probe amplification uncovered nine unrelated patients carrying a genetic abnormality in the complement factor H related 1 gene (CFHR1) that originates by recurrent gene conversion events between the CFH and CFHR1 genes. The novel CFHR1 mutants encode an FHR-1 protein with two amino acid substitutions, L290S and A296V, converting the FHR-1 C terminus into that of factor H (FH). Next-generation massive-parallel DNA sequencing (NGS) analysis did not detect these genetic abnormalities. In addition to the CFHR1 mutant, six patients carried the previously uncharacterized CFH-411T variant. In functional analyses, the mutant FHR-1 protein strongly competed the binding of FH to cell surfaces, impairing complement regulation, whereas the CFH-411T polymorphism lacked functional consequences. Carriers of the CFHR1 mutation presented with severe aHUS during adulthood; 57% of affected women in this cohort presented during the postpartum period. Analyses in patients and unaffected carriers showed that FH plasma levels determined by the nonmutated chromosome modulate disease penetrance. Crucially, in the activated endothelial (HMEC-1) cell assay, reduced FH plasma levels produced by the nonmutated chromosome correlated inversely with impairment of complement regulation, measured as C5b-9 deposition. Our data advance understanding of the genetic complexities underlying aHUS, illustrate the importance of performing functional analysis, and support the use of complementary assays to disclose genetic abnormalities not revealed by current NGS analysis., S.R.d.C. is supported by the Spanish “Ministerio de Economía y Competitividad-Federación Española de Enfermedades Raras (FEDER)” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608), and the Autonomous Region of Madrid (S2010/BMD-2316). S.R.d.C. is member of the “Centro de Investigaciones Biológicas Intramural Program “Molecular Machines for Better Life” (MACBET).” E.G.d.J. is supported by the Spanish “Ministerio de Economía y Competitividad” (RYC-2013-13395 and SAF2014-52339P). M.N. is supported by the Seventh Framework Programme European Union Project EURenOmics (305608). This study was also partially supported by Redes Tematicas De Investigacion Cooperativa En Salud, Red de Investigación Renal (RD06/0016/1002 and RD12/0028), the Instituto de Salud Carlos III, and the Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome, Pregnancy-associated atypical hemolytic uremic syndrome; a retrospective study from the Spanish Registry.

  • Huerta, Ana
  • Arjona, Emilia
  • Portoles, Jose
  • Lopez-Sanchez, Paula
  • Rabasco, Cristina
  • Espinosa, Mario
  • Cavero, Teresa
  • Blasco, Miquel
  • Cao, Mercedes
  • Manrique, Joaquin
  • Cabello-Chaves, Virginia
  • Suñer, Marta
  • Heras, Manuel
  • Fulladosa, Xavier
  • Belmar-Vega, Lara
  • Sempere, Amparo
  • Peralta, Carmen
  • Castillo, Lorena
  • Arnau, Alvaro
  • Praga, Manuel
  • Rodríguez de Córdoba, Santiago
34 p.-2 fig.-3 tab., Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) refers to the thrombotic microangiopathy resulting from uncontrolled complement activation during pregnancy or the postpartum period. Pregnancy-associated aHUS is a devastating disease for which there is a limited clinical understanding and treatment experience. Here we report a retrospective study to analyze the clinical and prognostic data of 22 cases of pregnancy-associated aHUS from the Spanish aHUS Registry under different treatments. Sixteen patients presented during the first pregnancy and as many as nine patients required hemodialysis at diagnosis. Identification of inherited complement abnormalities explained nine of the 22 cases, with CFH mutations and CFH to CFHR1 gene conversion events being the most prevalent genetic alterations associated with this disorder (66%). In thirteen of the cases, pregnancy complications were sufficient to trigger a thrombotic microangiopathy in the absence of genetic or acquired complement alterations. The postpartum period was the time with highest risk to develop the disease and the group shows an association of cesarean section with pregnancy-associated aHUS. Seventeen patients underwent plasma treatments with a positive renal response in only three cases. In contrast, ten patients received eculizumab with an excellent renal response in all, independent of carrying or not inherited complement abnormalities. Although the cohort is relatively small, the data suggest that pregnancy-associated aHUS is not different from other types of aHUS and suggest the efficacy of eculizumab treatment over plasma therapies. This study may be useful to improve prognosis in this group of aHUS patients., Work in this report was funded by the Instituto de Salud Carlos III: REDinREN (RD016/009 and RD012/0021) and Fondo de Investigaciones Sanitarias (ISCIII/FEDER) ref 13/02502 and ref 16/01685. SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R), the Seventh Framework Programme European Union Project EURenOmics (305608) and the Autonomous Region of Madrid (S2010/BMD-2316)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Complete functional characterization of disease-associated genetic variants in the complement factor H gene

  • Martín Merinero, Héctor
  • Pinto, Sheila
  • García-Fernández, Jesús
  • Arjona, Emilia
  • Tortajada, Agustín
  • Rodríguez de Córdoba, Santiago
30 p.-7 fig., Genetic analyses in atypical hemolytic uremic syndrome (aHUS) and C3-glomerulopathy (C3G) patients have provided an excellent understanding of the genetic component of the disease and informed genotype-phenotype correlations supporting an individualized approach to patient management and treatment. In this context, a correct categorization of the disease-associated gene variants is critical to avoid detrimental consequences for patients and their relatives. Here we describe a comprehensive procedure to measure levels and functional activity of complement regulator factor H (FH) encoded by CFH, the commonest genetic factor associated with aHUS and C3G, and present the results of the analysis of 28 uncharacterized, disease-associated, FH variants. Sixteen variants were not expressed in plasma and eight had significantly reduced functional activities that impact on complement regulation. In total, 24 of 28 CFH variants were unambiguously categorized as pathogenic and the nature of the pathogenicity fully documented for each. The data also reinforce the genotype-phenotype correlations that associate specific FH functional alterations with either aHUS or C3G and illustrate important drawbacks of the prediction algorithms dealing with variants located in FH functional regions. We also report that the novel aHUS-associated M823T variant is functionally impaired. This was unexpected and uncovered the important contribution of regions outside the N-terminal and C-terminal functional domains to FH regulatory activities on surfaces. Thus, our work significantly advances knowledge towards a complete functional understanding of the CFH genetic variability and highlights the importance of functional analysis of the disease-associated CFH variants., SRdeC is supported by the Spanish Ministerio de Economía y Competitividad/FEDER (grant number SAF2015-66287-R), the Seventh Framework Programme European Union Project EURenOmics (grantnumber 305608), and the Autonomous Region of Madrid (grantnumber S2010/BMD-2316)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Common and rare genetic variants of complement components in human disease

  • Goicoechea de Jorge, Elena
  • López-Lera, Alberto
  • Bayarri-Olmos, Rafael
  • Yébenes, Hugo
  • López-Trascasa, Margarita
  • Rodríguez de Córdoba, Santiago
49 p.-2 fig.-2 tab., Genetic variability in the complement system and its association with disease has been known for more than 50 years, but only during the last decade have we begun to understand how this complement genetic variability contributes to the development of diseases. A number of reports have described important genotype-phenotype correlations that associate particular diseases with genetic variants altering specific aspects of the activation and regulation of the complement system. The detailed functional characterization of some of these genetic variants provided key insights into the pathogenic mechanisms underlying these pathologies, which is facilitating the design of specific anti-complement therapies. Importantly, these analyses have sometimes revealed unknown features of the complement proteins. As a whole, these advances have delineated the functional implications of genetic variability in the complement system, which supports the implementation of a precision medicine approach based on the complement genetic makeup of the patients. Here we provide an overview of rare complement variants and common polymorphisms associated with disease and discuss what we have learned from them., SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad/FEDER” [SAF2015-66287-R] and the Autonomous Region of Madrid [S2017/BMD-3673]. SRdeC is member of the "CIB Intramural Program “Molecular Machines for Better Life” (MACBET)". MLT is supported by the Spanish “Ministerio de Economía y Competitividad/FEDER” [PI15-00255]. EGdeJ is supported by the Spanish “Ministerio de Economía y Competitividad/FEDER” [SAF2014-52339-P]. SRdeC and EGdeJ are also supported by the “Fundación Inocente Inocente” (Madrid, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome

  • Cavero, Teresa
  • Arjona, Emilia
  • Soto, Karina
  • Caravaca-Fontán, Fernando
  • Rabasco, Cristina
  • Bravo, Luis
  • de la Cerda, Francisco
  • Martín, Nadia
  • Blasco, Miquel
  • Ávila, Ana
  • Huerta, Ana
  • Cabello-Chaves, Virginia
  • Jarque, Ana
  • Alcázar, Concepción
  • Fulladosa, Xavier
  • Carbayo, Javier
  • Anaya, Sara
  • Cobelo, Carmen
  • Ramos, Natalia
  • Iglesias, Elena
  • Baltar, José
  • Martínez-Gallardo, Rocío
  • Pérez, Lourdes
  • Morales-Ruiz, E.
  • González, Roberto
  • Macía, Manuel
  • Draibe, Juliana
  • Pallardó, Luis
  • Quintana, Luis F.
  • Espinosa, Mario
  • Barros, Xoana
  • Pereira, Fernando
  • Cao, Mercedes
  • Moreno, Juan Antonio
  • Rodríguez de Córdoba, Santiago
  • Praga, Manuel
Malignant hypertension is listed among the causes of secondary thrombotic microangiopathy (TMA), but pathogenic mutations in complement genes have been reported in patients with hypertension-induced TMA. Here we investigated the frequency and severity of hypertension in 55 patients with primary atypical hemolytic uremic syndrome (aHUS). A genetic analysis was performed in all patients, and funduscopic examination was performed in all the patients with Grades 2 and 3 hypertension. A cohort of 110 patients with malignant hypertension caused by diseases other than aHUS served as control. Thirty-six patients with aHUS presented Grade 2 or Grade 3 hypertension and funduscopic examination showed malignant hypertension in 19. Genetic abnormalities in complement were found in 19 patients (37% among patients with malignant hypertension). Plasmapheresis was performed in 46 patients and 26 received eculizumab. Renal and hematological responses were significantly lower after plasmapheresis (24%) than after eculizumab (81%). Renal survival was significantly higher in patients treated with eculizumab (85% at one, three and five years) compared to patients who did not receive this treatment (54%, 46% and 41%), respectively. Response to eculizumab was independent of hypertension severity and the presence of complement genetic abnormalities. Among patients with malignant hypertension caused by other diseases the prevalence of TMA was very low (5%). Thus, severe and malignant hypertension are common among patients with aHUS and eculizumab treatment leads to a higher renal survival when compared to plasmapheresis. However, TMA is uncommon among patients presenting with malignant hypertension caused by diseases other than aHUS., Work in this study was supported by the Instituto de Salud Carlos III /Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grants PI13/02502, PICI14/00350, and PI16/01685 (to MP), and grants PI13/00802, PI14/00883 and PI17/00130 (to JAM.); the ISCIII/FEDER Programa Miguel Servet, grants CP10/00479 and CPII16/00017 (to JAM); the Spanish “Ministerio de Economía y Competitividad/FEDER” [SAF2015-66287-R] (to SRdeC); the Autonomous Region of Madrid (S2017/BMD-3673) (to SRdeC, EA and MP); Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to MP), the “Fundación Inocente” (Madrid, Spain).] (to SRdC), and the Spanish Society of Nephrology and Fundación Renal Ínigo Álvarez de Toledo (FRIAT) (to JAM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Noncanonical immunomodulatory activity of complement regulator C4BP(β-) limits the development of lupus nephritis

  • Luque, Ana
  • Serrano, Inmaculada
  • Ripoll, Èlia
  • Malta, Catarina
  • Gomá, Montserrat
  • Blom, Anna M.
  • Grinyó, Josep María
  • Rodríguez de Córdoba, Santiago
  • Torras, Joan
  • Aràn, Josep Maria
Lupus nephritis is a chronic autoimmune-inflammatory condition that can lead to end-stage kidney disease. Presently available immunosuppressive treatments for lupus nephritis are suboptimal and can induce significant side effects. Recently, we characterized a novel immunomodulatory activity of the minor isoform of the classical pathway complement inhibitor, C4BP(β-). We show here that C4BP(β-) treatment prevented the development of proteinuria and albuminuria, decreased significantly the formation of anti-dsDNA antibodies and, locally, mitigated renal glomerular IgG and C3 deposition and generation of apoptotic cells. There was a consequent histological improvement and increased survival in lupus-prone mice. The therapeutic efficacy of C4BP(β-) was analogous to that of the broad-acting immunosuppressant cyclophosphamide. Remarkably, a comparative transcriptional profiling analysis revealed that the kidney gene expression signature resulting from C4BP(β-) treatment turned out to be 10 times smaller than that induced by cyclophosphamide treatment. C4BP(β-) immunomodulation induced significant downregulation of transcripts relevant to lupus nephritis indicating immunopathogenic cell infiltration, including activated T cells (Lat), B cells (Cd19, Ms4a1, Tnfrsf13c), inflammatory phagocytes (Irf7) and neutrophils (Prtn3, S100a8, S100a9). Furthermore, cytokine profiling and immunohistochemistry confirmed that C4BP(β-), through systemic and local CXCL13 downregulation, was able to prevent ectopic lymphoid structures neogenesis in aged mice with lupus nephritis. Thus, due to its anti-inflammatory and immunomodulatory activities and high specificity, C4BP(β-) could be considered for further clinical development in patients with systemic lupus erythematosus., This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI16/00377 and PI13/00969,cofunded by FEDER funds/European Regional Development Fund—away to build Europe), the Generalitat de Catalunya (grant 2017SGR291 and Centres de Recerca de Catalunya [CERCA] Program), and Spherium Biomed S.L. JMA and SRdC are members of the Red de Excelencia “Complemento en salud y enfermedad” (SAF2016-81876- REDT). SRdC is supported by the Spanish Ministerio de Economía y Competitividad/FEDER (SAF2015-66287-R) and the Autonomous Region of Madrid (S2017/BMD-3673). JMA is sponsored by the Researchers Consolidation Program from the SNS-Dpt. Salut Generalitat de Catalunya (Exp. CES06/012)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gain-of-function mutation in complement C2 protein identified in a patient with aHUS

  • Urban, Aleksandra
  • Volokhina, Elena
  • Felberg, Anna
  • Stasiłojć, Grzegorz
  • Blom, Anna M.
  • Jongerius, Ilse
  • van den Heuvel, Lambertus
  • Thiel, Marcel
  • Oldziej, Stanislaw
  • Arjona, Emilia
  • Rodríguez de Córdoba, Santiago
  • Okrój, Marcin
15 p.-1 fig.-1 tab.-7 fig. supl., Supported by National Science Centre Poland (grant 2015/18/M/NZ6/00334), Ministerio de Economía y Competitividad/FEDER (grant SAF2015-66287-R), and Autonomous Region of Madrid (grant S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mycophenolate Mofetil in C3 glomerulopathy and pathogenic drivers of the disease

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Lucientes, Laura
  • Cavero, Teresa
  • Cabello-Chaves, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Lumbreras, Javier
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
12 p.-4 fig.-4 tab., BACKGROUND AND OBJECTIVES: C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components. Previous studies showed that treatment with corticosteroids plus mycophenolate mofetil (MMF) was associated with improved outcomes, although the genetic profile of these patients was not systematically analyzed. This study aims to analyze the main determinants of disease progression and response to this therapeutic regimen., DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, multicenter, observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases. Patients diagnosed with C3 glomerulopathy (n=81) or dense deposit disease (n=16) between January 1995 and March 2018 were enrolled. Multivariable and propensity score matching analyses were used to evaluate the association of clinical and genetic factors with response to treatment with corticosteroids and MMF as measured by proportion of patients with disease remission and kidney survival (status free of kidney failure)., RESULTS: The study group comprised 97 patients (84% C3 glomerulopathy, 16% dense deposit disease). Forty-two patients were treated with corticosteroids plus MMF, and this treatment was associated with a higher rate of remission and lower probability of kidney failure (79% and 14%, respectively) compared with patients treated with other immunosuppressives (24% and 59%, respectively), or ecluzimab (33% and 67%, respectively), or conservative management (18% and 65%, respectively). The therapeutic superiority of corticosteroids plus MMF was observed both in patients with complement abnormalities and with autoantibodies. However, patients with pathogenic variants in complement genes only achieved partial remission, whereas complete remissions were common among patients with autoantibody-mediated forms. The main determinant of no remission was baseline proteinuria. Relapses occurred after treatment discontinuation in 33% of the patients who had achieved remission with corticosteroids plus MMF, and a longer treatment length of MMF was associated with a lower risk of relapse., CONCLUSIONS: The beneficial response to corticosteroids plus MMF treatment in C3 glomerulopathy appears independent of the pathogenic drivers analyzed in this study., Work in this study was supported by the Instituto de Salud CarlosIII/ Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M. Praga), and the Autonomous Region of Madrid (S2017/BMD-3673) (to S. Rodríguez de Córdoba and M. Praga).E. Goicoechea de Jorge is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades” (RYC-2013-13395 and RTI2018-095955-B-100). S. Rodríguez de Córdoba is supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Familial risk of developing atypical hemolytic-uremic syndrome, Familial risk of developing aHUS

  • Arjona, Emilia
  • Huerta, Ana
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
13 p.-1 fig.-1 tab.+10 p.-3 tab. (mat. supl.), .Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening disease that in most cases progresses to end-stage kidney disease.1 Rare pathogenic mutations in complement components or regulatory proteins play a crucial role in the pathogenesis of aHUS in 50% to 60% of patients.2-4 These rare variants cause defective regulation of the complement alternative pathway in the endothelial cell surface, which triggers episodes of thrombotic microangiopathy in the renal microvasculature and other vital organs.5-11 Finding complement pathogenic mutations in genetic analyses, or not finding them, improves diagnosis and facilitates a personalized treatment with eculizumab, a humanized monoclonal antibody that avoids the pathological consequences of cell surface complement dysregulation.1 Genetic analyses are widely used to help clinically diagnose aHUS, and they can help identify numerous asymptomatic relatives who carry different loads of aHUS genetic risk factors. A recurring..., This work was developed under the supervision of the Spanish Registry of atypical Hemolytic Uremic Syndrome and C3-Glomerulopathy (aHUS/C3G) and was supported by the Spanish Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287-R and Autonomous Region of Madrid grant S2017/BMD-3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The relevance of the MCP risk polymorphism to the outcome of aHUS associated with C3 mutations. A case report

  • Lumbreras, Javier
  • Subías, Marta
  • Espinosa, Natalia
  • Ferrer, Juana María
  • Arjona, Emilia
  • Rodríguez de Córdoba, Santiago
6 p.-2 fig.-1 tab., Thrombotic microangiopathy (TMA) has different etiological causes, and not all of them are well understood. In atypical hemolytic uremic syndrome (aHUS), the TMA is caused by the complement dysregulation associated with pathogenic mutations in complement components and its regulators. Here, we describe a pediatric patient with aHUS in whom the relatively benign course of the disease confused the initial diagnosis. A previously healthy 8-year-old boy developed jaundice, hematuria, hemolytic anemia, thrombopenia, and mild acute kidney injury (AKI) in the context of a diarrhea without hypertension nor oliguria. Spontaneous and complete recovery was observed from the third day of admission. Persistent low C3 plasma levels after recovery raised the suspicion for aHUS, which prompted clinicians to discard the initial diagnosis of Shigatoxin-associated HUS (STEC-HUS). A thorough genetic and molecular study of the complement revealed the presence of an isolated novel pathogenic C3 mutation. The relatively benign clinical course of the disease as well as the finding of a de novo pathogenic C3 mutation are remarkable aspects of this case. The data are discussed to illustrate the benefits of identifying the TMA etiological factor and the relevant contribution of the MCP aHUS risk polymorphism to the disease severity., SR was supported by the Spanish Ministerio de Economía y Competitividad-FEDER (SAF2015-66287R) and the Autonomous Region of Madrid (S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Molecular bases for the association of FHR-1 with atypical hemolytic uremic syndrome and other diseases, Short title: Molecular understanding of FHR-1 function

  • Martín Merinero, Héctor
  • Subías, Marta
  • Pereda, Amaia
  • Gomez-Rubio, Elena
  • Juana-López, Lucía
  • Fernández Rivera, Constantino
  • Goicoechea de Jorge, Elena
  • Martín-Santamaría, Sonsoles
  • Cañada, F. Javier
  • Rodríguez de Córdoba, Santiago
33 p.-7 fig., Factor H-related proteins (FHRs) are a group of partly characterized complement proteins that are thought to promote complement activation by competing binding of factor H (FH) to surface-bound C3b. Among them, FHR-1 is remarkable because is associated with atypical hemolytic uremic syndrome (aHUS) and other important diseases. Using a combination of biochemical, immunological, nuclear magnetic resonance and computational approaches, we have characterized a series of FHR-1 mutants (including two associated with aHUS) and have unraveled the molecular bases of the so-called de-regulation activity of FHR-1. In contrast with FH,FHR-1 lacks the capacity to bind sialic acids, which prevents C3b-binding competition between FH and FHR-1 in host cell surfaces. aHUS-associated FHR-1 mutants are pathogenic because they have acquired the capacity to bind sialic acids, which increases FHR-1 avidity for surface-bound C3-activated fragments and results in C3b-binding competition with FH. FHR-1 binds to native C3, in addition to C3b, iC3b and C3dg.This unexpected finding suggests that the mechanism by which surface-bound FHR-1 promotes complement activation is the attraction of native C3 to the cell surface. Whilst C3b-binding competition with FH is limited to aHUS-associated mutants, all surfacebound FHR-1 promote complement activation, which is delimited by the FHR-1/FH activity ratio. Our data indicate that the FHR-1 de-regulation activity is important to sustain complement activation and C3 deposition at complement activating surfaces.They also support that abnormally elevated FHR-1/FH activity ratios would perpetuate a pathological complement dysregulation at complement activating surfaces, which may explain the association of FHR-1 quantitative variations with diseases., SRdeC, FJC and SMS are supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” grants (SAF2015-66287-R, RTI2018-094751-B-C22, and CTQ2017-88353-R, respectively) and the Autonomous Region of Madrid (S2017/BMD-3673). EGdeJ is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades-FEDER (RYC-2013-13395 and RTI2018-095955-B-100)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Detection of genetic rearrangements in the regulators of complement activation RCA cluster by high-throughput sequencing and MLPA

  • García-Fernández, Jesús
  • Vilches, Susana
  • Olavarrieta, Leticia
  • Pérez Pérez, J.
  • Rodríguez de Córdoba, Santiago
20 p.-6 fig.-3 tab., The regulators of complement activation (RCA) gene cluster in 1q31-1q32 includes most of the genes encoding complement regulatory proteins. Genetic variability in the RCA gene cluster frequently involve copy number variations (CNVs), a type of chromosome structural variation causing alterations in the number of copies of specific regions of DNA. CNVs in the RCA gene cluster often relate with gene rearrangements that result in the generation of novel genes, carrying internal duplications or deletions, and hybrid genes, resulting from the fusion or exchange of genetic material between two different genes. These gene rearrangements are strongly associated with a number of rare and common diseases characterized by complement dysregulation. Identification of CNVs in the RCA gene cluster is critical in the molecular diagnostic of these diseases. It can be done by bioinformatics analysis of DNA sequence data generated by massive parallel sequencing techniques (NGS, next generation sequencing) but often requires special techniques like multiplex ligation-dependent probe amplification (MLPA). This is because the currently used massive parallel DNA sequencing approaches do not easily identify all the structural variations in the RCA gene cluster. We will describe here how to use the MLPA assays and two computational tools to analyze NGS data, NextGENe and ONCOCNV, to detect CNVs and gene rearrangements in the RCA gene cluster., SRdeC is supported by the Spanish “Ministerio de Economía y Competitividad-FEDER” (SAF2015-66287R, PID2019-104912RB-I00, RTC-2016-4635-1 and the Autonomous Region of Madrid (S2017/BMD-3673). Secugen has received a soft loan from the Spanish “Ministerio de Economía y Competitividad” Retos Program RTC-2016-4635-1 cofinanced by FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study

  • Portoles, Jose
  • Huerta, Ana
  • Arjona, Emilia
  • Gavela, Eva
  • Agüera, Marisa
  • Jiménez, Carlos
  • Cavero, Teresa
  • Marrero, Domingo
  • Rodríguez de Córdoba, Santiago
  • Diekmann, Fritz
8 p.-2 fig.-3 tab., Background: Kidney transplantation (KTx) is a strong trigger for the development of either recurrent or de novo atypical haemolytic uraemic syndrome (aHUS). According to previous studies, eculizumab (ECU) is effective for prophylaxis and for treatment of recurrence., Methods: We evaluated the experiences of Spanish patients with recurrent and de novo aHUS associated with KTx, treated or not treated with ECU. In the de novo group, we classified patients as having early de novo (during the first month) or late de novo aHUS (subsequent onset)., Results: We analysed 36 cases of aHUS associated with KTx. All of the 14 patients with pre-KTx diagnosis of aHUS were considered to have high or moderate risk of recurrence. Despite receiving grafts from suboptimal donors, prophylactic ECU was effective for avoiding recurrence. The drug was stopped only in two cases with low–moderate risk of recurrence and was maintained in high-risk patients with no single relapse. There were 22 de novo aHUS cases and 16 belonged to the early de novo group. The median time of onset in the late group was 3.4 years. The early group had a better response to ECU than the late group, probably due to earlier diagnosis and use of the drug. No genetic pathogenic variant was detected in de novo aHUS cases, suggesting a secondary profile of the disease. ECU was stopped in all de novo patients with no relapses. ECU was well tolerated in all cases., Conclusions: Both groups (pre-aHUS and de novo) presented different clinical profiles, management approaches and outcomes. One should consider aHUS regardless of time after KTx. Genetic studies are crucial to stratify risks of relapse and to determine necessary lengths of treatment. We suggest short ECU treatment for de novo cases without pathogenic mutation and that ECU treatment be considered pre-emptively for patients with moderate or high risk of recurrence., This project was co-founded by Public Research Network REDinREN ISCIII 16/009/009 and the SENTRA group. S.R.d.C. is supported by the Spanish Ministerio de Economía y Competitividad-FEDER (SAF2015-66287R) and the Autonomous Region of Madrid (S2017/BMD-3673)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy

  • Caravaca-Fontán, Fernando
  • Díaz-Encarnación, Montserrat M.
  • Cabello, Virginia
  • Ariceta, Gema
  • Quintana, Luis F.
  • Marco, Helena
  • Barros, Xoana
  • Ramos, Natalia
  • Rodríguez-Mendiola, Nuria
  • Cruz, Sonia
  • Fernández-Juárez, Gema
  • Rodríguez, Adela
  • Pérez de José, Ana
  • Rabasco, Cristina
  • Rodado, Raquel
  • Fernández, Loreto
  • Pérez Gómez, Vanessa
  • Ávila, Ana
  • Bravo, Luis
  • Espinosa, Natalia
  • Allende, Natalia
  • Sánchez de la Nieta, María Dolores
  • Rodríguez, Eva
  • Olea, Teresa
  • Melgosa, Marta
  • Huerta, Ana
  • Miquel, Rosa
  • Mon, Carmen
  • Fraga, Gloria
  • de Lorenzo, Alberto
  • Draibe, Juliana
  • Cano-Megías, Marta
  • González, Fayna
  • Shabaka, Amir
  • López-Rubio, María Esperanza
  • Fenollosa, María Ángeles
  • Martín-Penagos, L.
  • Da Silva, Iara
  • Alonso Titos, Juana
  • Rodríguez de Córdoba, Santiago
  • Goicoechea de Jorge, Elena
  • Praga, Manuel
  • Spanish Group for the Study of Glomerular Diseases (GLOSEN)
11 p.-4 fig.-4 tab., Introduction: The association between a change in proteinuria over time and its impact in kidney prognosis has not been analyzed in C3 glomerulopathy. This study aims to investigate the association between the longitudinal change in proteinuria and the risk of kidney failure., Methods: Retrospective, multicenter observational cohort study in 35 nephrology departments belonging to the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Patients diagnosed with C3 glomerulopathy between 1995 and 2020 were enrolled. A joint modeling of linear mixed-effects models was applied to assess the underlying trajectory of a repeatedly measured proteinuria, and a Cox model to evaluate the association of this trajectory with the risk of kidney failure., Results: The study group consisted of 85 patients, 70 C3 glomerulonephritis and 15 dense deposit disease, with a median age of 26 years (range 13-41). During a median follow-up of 42 months, 25 patients reached kidney failure. The longitudinal change in proteinuria showed a strong association with the risk of this outcome, with a doubling of proteinuria levels resulting in a 2.5-fold increase of the risk. A second model showed that a ≥ 50% proteinuria reduction over time was significantly associated with a lower risk of kidney failure (HR: 0.79; 95% CI : 0.56-0.97; p < 0.001). This association was also found when the ≥50% proteinuria reduction was observed within the first 6 and 12 months of follow-up., Conclusion: The longitudinal change in proteinuria is strongly associated with the risk of kidney failure. The change in proteinuria over time can provide clinicians a dynamic prediction of kidney outcomes., This study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (ISCIII/FEDER) grant PI16/01685 and PI19/1624, and Red de Investigación Renal (RedInRen) (RD12/0021/0029) (to M.P.), the Autonomous Region of Madrid (S2017/BMD-3673) (to M.P.); E.G.d.J. was supported by the Spanish ‘Ministerio de Ciencia, Innovación y Universidades’ (RYC-2013-13395 and RTI2018-095955-B-100); S.R.d.C. was supported by Ministerio de Economía y Competitividad/FEDER grant SAF2015-66287R and Autonomous Region of Madrid grant S2017/BMD3673., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor

  • Fernández, Francisco J.
  • Santos-López, Jorge
  • Martínez-Barricarte, Rubén
  • Querol-García, Javier
  • Martín Merinero, Héctor
  • Navas-Yuste, Sergio
  • Savko, Martin
  • Shepard, William E.
  • Rodríguez de Córdoba, Santiago
  • Vega, María Cristina
16 p.-9 fig., Complement activation on cell surfaces leads to the massive deposition of C3b, iC3b, and C3dg, the main complement opsonins. Recognition of iC3b by complement receptor type 3 (CR3) fosters pathogen opsonophagocytosis by macrophages and the stimulation of adaptive immunity by complement-opsonized antigens. Here, we present the crystallographic structure of the complex between human iC3b and the von Willebrand A inserted domain of the α chain of CR3 (αI). The crystal contains two composite interfaces for CR3 αI, encompassing distinct sets of contiguous macroglobulin (MG) domains on the C3c moiety, MG1-MG2 and MG6-MG7 domains. These composite binding sites define two iC3b-CR3 αI complexes characterized by specific rearrangements of the two semi-independent modules, C3c moiety and TED domain. Furthermore, we show the structure of iC3b in a physiologically-relevant extended conformation. Based on previously available data and novel insights reported herein, we propose an integrative model that reconciles conflicting facts about iC3b structure and function and explains the molecular basis for iC3b selective recognition by CR3 on opsonized surfaces., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (to M.C.V.) and PID2019-104912RB-I00 (to S.R.C.), and Spanish Ministerio de Economía y Competitividad-FEDER grants SAF2015-72961-EXP (to M.C.V.) and SAF2015-66287-R (to S.R.C.). It was also funded by Grant S2017/BMD-3673 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to S.R.C. and M.C.V.), and the CSIC Special Intramural Grant PIE-201620E064 (to M.C.V.). It was additionally supported by the Network of Excellence Complement in Health and Disease (SAF2016-81876-REDT). SRC was also supported by the CIBER de Enfermedades Raras. JSL acknowledges the support of the PhD program in Molecular Biosciences of the Universidad Autónoma de Madrid (UAM) and the Ministry of Education, Culture and Sports of Spain (FPU Grant 17/06090). SNY acknowledges the support of the PhD program in Biochemistry, Molecular Biology and Biomedicine of the Universidad Complutense de Madrid (UCM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hidden side of complement regulator C4BP: dissection and evaluation of its immunomodulatory activity

  • Serrano, Inmaculada
  • Luque, Ana
  • Mitjavila, F.
  • Blom, Anna M.
  • Rodríguez de Córdoba, Santiago
  • Vega, María Cristina
  • Torras, Joan
  • Aran, Josep M.
16 p.-9 fig., C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP α-chain (PRP6-HO7) is sufficient to “reprogram” monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-α. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(β-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the “Departament de Recerca i Universitats de la Generalitat de Catalunya” (grants 2019PROD00081 and 2017SGR291), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Dr. Vega is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades/FEDER” [RTI2018-102242-B-I00]. Dr. Rodriguez de Córdoba is supported by the Spanish “Ministerio de Economia y Competitividad/FEDER [SAF2015-66287-R]. Dr. Vega and Dr. Rodriguez de Córdoba are also funded by the Autonomous Region of Madrid [S2017/BMD-3673] and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) [SGL2103020]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C4BP(β-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients

  • Serrano, Inmaculada
  • Luque, Ana
  • Ruiz-Cerulla, Alexandra
  • Navas, Sergio
  • Blom, Anna M.
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
  • Rodríguez-Moranta, Francisco
  • Guardiola, Jordi
  • Aran, Josep M.
16 p.-9 fig.-1 tab., The most recent and promising therapeutic strategies for inflammatory bowel disease (IBD) have engaged biologics targeting single effector components involved in major steps of the immune-inflammatory processes, such as tumor necrosis factor, interleukins or integrins. Nevertheless, these molecules have not yet met expectations regarding efficacy and safety, resulting in a significant percentage of refractory or relapsing patients. Thus, novel treatment options are urgently needed. The minor isoform of the complement inhibitor C4b-binding protein, C4BP(β-), has been shown to confer a robust anti-inflammatory and immunomodulatory phenotype over inflammatory myeloid cells. Here we show that C4BP(β-)-mediated immunomodulation can significantly attenuate the histopathological traits and preserve the intestinal epithelial integrity in dextran sulfate sodium (DSS)-induced murine colitis. C4BP(β-) downregulated inflammatory transcripts, notably those related to neutrophil activity, mitigated circulating inflammatory effector cytokines and chemokines such as CXCL13, key in generating ectopic lymphoid structures, and, overall, prevented inflammatory immune cell infiltration in the colon of colitic mice. PRP6-HO7, a recombinant curtailed analogue with only immunomodulatory activity, achieved a similar outcome as C4BP(β-), indicating that the therapeutic effect is not due to the complement inhibitory activity. Furthermore, both C4BP(β-) and PRP6-HO7 significantly reduced, with comparable efficacy, the intrinsic and TLR-induced inflammatory markers in myeloid cells from both ulcerative colitis and Crohn’s disease patients, regardless of their medication. Thus, the pleiotropic anti-inflammatory and immunomodulatory activity of PRP6-HO7, able to “reprogram” myeloid cells from the complex inflammatory bowel environment and to restore immune homeostasis, might constitute a promising therapeutic option for IBD., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the “Departament de Recerca i Universitats de la Generalitat de Catalunya” (grants 2019PROD00081, 2021INNOV00020, and 2021SGR00521), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Additionally, the project that gave rise to these results has received funding from the “La Caixa” Foundation and the European Institute of Innovation and Technology, EIT (body of the European Union that receives support from the European Union’s Horizon 2020 research and innovation programme), under the grant agreement CI22–00230. Likewise, this study was financially promoted by the “hna Foundation”. Dr. Vega is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades/FEDER” [RTI2018–102242-B-I00]. Dr. Rodriguez de Córdoba is supported by the Spanish “Ministerio de Economia y Competitividad/FEDER [SAF2015–66287-R]. Dr. Vega and Dr. Rodriguez de Córdoba are also funded by the Autonomous Region of Madrid [S2022/BMD-7278] and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (”PTI Salud Global”) [SGL2103020]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Thrombotic microangiopathy in patients with malignant hypertension

  • Cavero, Teresa
  • Auñón, Pilar
  • Caravaca-Fontán, Fernando
  • Trujillo, Hernando
  • Arjona, Emilia
  • Morales, Enrique
  • Guillén, Elena
  • Blasco, Miquel
  • Rabasco, Cristina
  • Espinosa, Mario
  • Blanco, Marta
  • Rodríguez-Magariños, Catuxa
  • Cao, Mercedes
  • Ávila, Ana
  • Huerta, Ana
  • Rubio, Esther
  • Cabello-Chaves, Virginia
  • Barros, Xoana
  • Goicoechea de Jorge, Elena
  • Rodríguez de Córdoba, Santiago
  • Praga, Manuel
10 p.-4 fig.-4 tab., Background: Thrombotic microangiopathy (TMA) is a complication of malignant hypertension (mHTN) attributed to high blood pressure (BP). However, no studies have investigated in patients with mHTN of different aetiologies whether the presence of TMA is associated with specific causes of mHTN., Methods: We investigated the presence of TMA (microangiopathic haemolytic anaemia and thrombocytopenia) in a large and well-characterized cohort of 199 patients with mHTN of different aetiologies [primary HTN 44%, glomerular diseases 16.6%, primary atypical haemolytic uraemic syndrome (aHUS) 13.1%, renovascular HTN 9.5%, drug-related HTN 7%, systemic diseases 5.5%, endocrine diseases 4.5%]. Outcomes of the study were kidney recovery and kidney failure., Results: Patients with TMA [40 cases (20.1%)] were younger, were more likely female and had lower BP levels and worse kidney function at presentation. Their underlying diseases were primary aHUS (60%), drug-related mHTN (15%), glomerular diseases [all of them immunoglobulin A nephropathy (IgAN); 10%], systemic diseases (10%) and primary HTN (5%). The presence of TMA was 92.3% in primary aHUS, 42.9% in drug-related HTN, 36.4% in systemic diseases, 12.1% in glomerular diseases and 2.3% in primary HTN. No patient with renovascular HTN or mHTN caused by endocrine diseases developed TMA, despite BP levels as high as patients with TMA. A higher proportion of TMA patients developed kidney failure as compared with patients without TMA (56.4% versus 38.9%, respectively)., Conclusions: The presence of TMA in patients with mHTN should guide the diagnosis towards primary aHUS, drug-related mHTN, some systemic diseases and IgAN, while it is exceptional in other causes of mHTN., Work in this study was supported by the Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional [ISCIII/FEDER;grants PI13/02502 and PICI14/00350 (to M.P.) and PI16/01685 and PI19/01624 (to M.P. and T.C.)]; the Spanish Ministerio de Economía y Competitividad/FEDER [SAF2015-66287-R and PID2019-104912RB-I00 (to S.R.d.C.)]; the Spanish ‘Ministerio de Ciencia Innovación y Universidades’ [RTI2018-095955-B-100 (to E.G.J.)]; the Autonomous Region of Madrid [S2017/BMD-3673 (to E.G.J., S.R.d.C. and M.P.)] and Red de Investigación Renal [RD12/0021/0029 (to M.P.)]., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from the Gram-positive bacterial pathogen A. vaginae, an immunoevasive factor that interacts with the human C5a anaphylatoxin

  • Querol García, Javier
  • Fernández, Francisco J.
  • Marín Marín, Ana Victoria
  • Gómez, Sara
  • Fullà, Daniel
  • Melchor Tafur, Cecilia
  • Franco Hidalgo, Virginia
  • Albertí, Sebastián
  • Juanhuix, Jordi
  • Rodríguez de Córdoba, Santiago
  • Regueiro González-Barros, José Ramón
  • Vega, María Cristina
The Gram-positive anaerobic human pathogenic bacterium Atopobium vaginae causes most diagnosed cases of bacterial vaginosis as well as opportunistic infections in immunocompromised patients. In addition to its well-established role in carbohydrate metabolism, D-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from Streptococcus pyogenes and S. pneumoniae have been reported to act as extracellular virulence factors during streptococcal infections. Here, we report the crystal structure of GAPDH from A. vaginae (AvGAPDH) at 2.19 Å resolution. The refined model has a crystallographic Rfree of 22.6%. AvGAPDH is a homotetramer wherein each subunit is bound to a nicotinamide adenine dinucleotide (NAD+) molecule. The AvGAPDH enzyme fulfills essential glycolytic as well as moonlight (non-glycolytic) functions, both of which might be targets of chemotherapeutic intervention. We report that AvGAPDH interacts in vitro with the human C5a anaphylatoxin and inhibits C5a-specific granulocyte chemotaxis, thereby suggesting the participation of AvGAPDH in complement-targeted immunoevasion in a context of infection. The availability of high-quality structures of AvGAPDH and other homologous virulence factors from Gram-positive pathogens is critical for drug discovery programs. In this study, sequence and structural differences between AvGAPDH and related bacterial and eukaryotic GAPDH enzymes are reported in an effort to understand how to subvert the immunoevasive properties of GAPDH and evaluate the potential of AvGAPDH as a druggable target.